Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2011
June 1, 2011
- Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
- GlobeImmune presents cancer clinical trial data at ASCO
- Analysis of Surfaxin Data Presented in First Peer-Reviewed Manuscript Describing the Consequences of Reintubation in Preterm Neonates
- Bavarian Nordic Announces Presentation of PROSTVAC Data at the 2011 ASCO Annual Meeting
- MDxHealth's Methylation Based Companion Diagnostics Enables Better Personalized Treatment in Brain Cancer
- Zealand Pharma - Additional positive Phase III results with Lyxumia® (lixisenatide) for the treatment of Type 2 diabetes
- Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
- Argos Therapeutics' Arcelis Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
- Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
- AMRI Announces Successful Completion of Phase I Clinical Study of Obesity Compound
- Teva Announces Data on Granulocyte Colony Stimulating Factor Compounds for the Prevention of Chemotherapy-Induced Neutropenia in Breast Cancer Patients
June 2, 2011
- Zalicus to Present at the 10th Annual World Pharma Conference
- Fraunhofer USA CMB Announces Positive Phase 1 Interim Results for Its Plant-Produced H1N1 Influenza Vaccine
- AVEO's Ficlatuzumab in Combination with Gefinitib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO
- GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair in COPD
- Biovest Announces that BiovaxID Personalized Cancer Vaccine is Featured in Journal of Clinical Oncology
- Final Analysis from AVEO Pharmaceuticals' Phase 2 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma Presented at ASCO
- iBio Announces Positive H1N1 Influenza Vaccine Clinical Trial Results
- Phase II Study Results Showed Eisai's Lenvatinib (E7080) Demonstrated an Objective Response Rate of 59% in Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer
- New Data Underscore Nausea is Significantly Debilitating Symptom of Migraine, Potentially Impacting Millions of Patients, Particularly Women
June 3, 2011
- ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
- ZYTIGA Data to be Presented at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting
- Many migraine sufferers can predict their migraine attack -- may create new treatment possibilities
- New Strategy to Combat Cystitis
- Novel 'Prodrug' Alleviates Symptoms in Huntington's and Alzheimer's Mice
- Older Men More Likely to Lose the Ability to Orgasm Due to Gabapentin According to Busm Researchers
- EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
- YM BioSciences Reports Interim Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASCO
- Five-Year Follow-Up Data for SPRYCEL (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to Gleevec®*
June 6, 2011
- Second Phase 3 Study of YERVOY (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
- Genentech Announces Vemurafenib Improved Survival in People With Metastatic Melanoma Who Have BRAF V600 Mutations
- Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
- Algeta Announces Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients With Castration-Resistant Prostate Cancer That Has Spread to the Bone
- Biogen Idec Reports Positive Data from AVONEX Dose Titraion Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers
- Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
- Geron Highlights ASCO/AACR Joint Session: Telomeres and Telomerase in Cancer
- Biogen Idec Reports Positive Data from AVONEX Dose Titration Study at 2011 Annual Meeting of the Consortium of Multiple Sclerosis Centers
- Onconova Presents Positive Data on ESTYBON (rigosertib, ON 01910.Na), a Novel Phase III Anti-Cancer Agent, at ASCO 2011
- Ligand Presents Phase IIa Data on Captisol-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011
- Phase III Study of Dacogen (decitabine) for Injection in Acute Myeloid Leukemia (AML) Presented at ASCO
- Researchers Report New Data on TB4's Ability to Reduce Heart Attack Damage
- Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
- Eisai and Janssen Announce the Presentation of DACOGEN (decitabine) Data at ASCO from a Phase III Study in Patients with Acute Myeloid Leukemia
- Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
- Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
- New Approaches Open up in Spinal Muscular Atrophy
June 7, 2011
- Cipher Pharmaceuticals Announces Top-Line Results of Cip-Isotretinoin Phase III Safety Study
- Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate
- Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
- Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product (Lipegfilgrastim) in Breast Cancer Patients
- Corlux Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome
- Antisense Presents Excellent Safety Profile of Trabedersen at ASCO 2011
- Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
- Silence Therapeutics? Atu027 Demonstrates Promising Antitumor Activity in Phase I Study Presented at ASCO
- Dacogen (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia
June 8, 2011
- Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure
- RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM (E75) and Trastuzumab Breast Cancer at ASCO
- 4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis
- VentiRx Pharmaceuticals Presents Results from Phase 1 Clinical Trial of VTX-2337, a Novel TLR8 Agonist, in Patients with Advanced Solid Tumors at American Society of Clinical Oncology Annual Meeting
- ZIOPHARM Announces Initial Positive Data Presented at 2011 ASCO Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans
- Vical - Vical Presents Positive Correlation Between Response and Survival at ASCO for Completed Allovectin Melanoma Trials
- FOLOTYN Data to be Presented at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma
- Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at the 14th World Conference on Lung Cancer
- Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer
- Rho Contributes to a Major Advance in Treating Severe Form of Vasculitis
- Four New Studies Presented at the World Congress of Dermatology Show Potential in Treating Precancerous Skin Disease, Actinic Keratosis
June 9, 2011
- Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
- Novartis Candidate Vaccine Bexsero Shows Significant Potential in Providing Broad Coverage Against Meningococcal Serogroup B Infections
- Mesoblast Limited Revascor Increases Blood Supply to Damaged Heart Muscle
- XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity
- BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference
- Post Hoc Analysis from RECOVER Study Examined Effects of Neupro (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinson's Disease
- Abbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
June 10, 2011
- the Combination of Palonosetron and Aprepitant Shows Superior Protection From Significant Nausea and Vomiting Than Daily Granisetron in Patients Receiving High Dose Chemotherapy As Conditioning Prior to Stem Cell Transplantation
- Chelsea Therapeutics Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension Presented at MDS 15th International Congress of Parkinson's Disease and Movement Disorders
- Tesetaxel Results from Multiple Dose-Ranging Clinical Trials Updated at ASCO
- New Data On Xeomin (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS)
- Insmed's ARIKACE Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
- Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism's Congress
- Avila Therapeutics Presents Data Demonstrating the Relevance of its Btk Inhibitor, AVL-292, in B Cell Malignancies such as CLL
- Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association
- New Post Hoc Analyses Examined the Effects of Neupro (Rotigotine Transdermal System) on Daytime Functioning, Daytime Symptoms, Pain and Mood in Restless Legs Syndrome
- Millennium and Seattle Genetics Present Clinical Data on ADCETRIS (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
- Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis
June 13, 2011
- Millennium and Seattle Genetics Present Clinical Data on ADCETRIS (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting
- Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
- CytRx Reports Positive Preliminary Results from ENABLE Phase 2 Clinical Trial with Bafetinib in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
June 14, 2011
- Interim Data From Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations
- CytRx Reports Positive Phase 2 Preliminary Drug Trial Results for B-Cell Leukemia Patients
- Randomized Study Combining L-Methylfolate with Antidepressant Shows Significant Boost in Patient Response
- Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
- DP-b99 Phase III MACSI Study Protocol Published in International Journal of Stroke
- Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up
- Novartis candidate vaccine Bexsero shows significant potential in providing broad coverage against meningococcal serogroup B infections
June 15, 2011
- Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
- LifeSource Announces New Study Findings Available on Deaths Related to Prescription Opioid Therapy
- OHSU Research Finds Botox Treats Wrinkles with Less Frequent Injections
- MEDA: New Positive Study Results Presented for Dymista
- Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer
- Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Clinical Data at International Conference on Malignant Lymphoma
- Alkermes Initiates Clinical Study of ALKS 5461 for Treatment-Resistant Depression
- Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
- Phase 2 Data on Provectus's PV-10 for Metastatic Melanoma to Be Presented at Two Upcoming Conferences
- Phase 2 Study of SKP-1041 for Sleep Maintenance Insomnia Shows Significant Reduction of Mid-Night Awakenings without Next-Day Cognitive Impairment
June 16, 2011
- Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
- Cubist Announces Positive Results from Two Phase 2 Trials, CXA-201 and CDAD Program
- ARIAD Announces Broader Profile of Its Investigational Lung Cancer Drug Candidate, AP26113, Showing Dual Inhibition of ALK and EGFR ? New Preclinical Data Highlight Potential in Resistant Lung Cancer Due to Mutated EGFR
- BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine
- Aegis CNS licensee, Neurelis, Inc., announces exciting Phase I clinical trial results
- TONIX Pharmaceuticals Presents Findings on the Effects of Bedtime Very Low Dose (VLD) Cyclobenzaprine (CBP) on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome
June 17, 2011
- Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
- New Australian drug shows positive response in patients with multiple myeloma blood cancer
- Pixantrone in Combination with Fludarabine, Dexamethasone and Rituximab Produces High Rates of Complete Remissions in Patients with Relapsed or Refractory Indolent Non-Hodgkins Lymphoma
- Data Suggests Treatment with FOLOTYN Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Relapsed or Refractory Peripheral T-Cell Lymphoma
June 20, 2011
- Curis Announces Presentation of Positive Vismodegib Pivotal Clinical Data in Advanced Basal Cell Carcinoma
- Pivotal Study Showed Vismodegib Helped Shrink Tumors or Heal Lesions in People with Rare Form of Advanced Skin Cancer
- Spectrum Pharmaceuticals' ZEVALIN Was Highlighted During Oral Presentations and Abstracts at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland
- Alnylam Scientists and Collaborators Publish New Article in Nature Describing Discovery of Central Gene in Mitochondrial Physiology
- Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
June 21, 2011
- Pfizer's Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury
- Chelsea Therapeutics Announces Successful Completion of Northera QTc Study
- CEL-SCI Corporation Announces Data Showing Cancer Drug Multikine Lowers Cholesterol in Clinical Studies
June 22, 2011
- Multiple Presentations Featuring Long-term QNEXA Data at the American Diabetes Association 71st Scientific Sessions
- Oxford BioMedica Announces Ocular Programme Update
- Texas Children's Fetal Center Study Shows Perinatal Management Improves Outcomes for Babies with Congenital Diaphragmatic Hernia
- Lipid Therapeutics Announces Positive Topline Phase IIb Results With LT-02 in Patients With Ulcerative Colitis
- Intensive-Dose Statin Therapy Associated With Increased Risk of Diabetes
- Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
- Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
- Certain Drugs Lower Risk of Diabetes for Patients With Rheumatoid Arthritis or Psoriasis
- Gold nanoparticles help earlier diagnosis of liver cancer
- Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
June 23, 2011
- MAP Pharmaceuticals to Present Data on LEVADEX at the 15th Congress of the International Headache Society
- MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
- CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
- Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue
- Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity
- New England Journal of Medicine Publishes Data From Two Phase 3 Studies of Incivek (telaprevir) in Hepatitis C
- Eliquis (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study
- Curcumin is Key to Unlocking Cancer Epigenetic Code - EuroPharma
- Angioplasty With Stents May Be Safe in Long-Term for Low-Risk Heart Patients
- Data on MLN8237, an Investigational Aurora A Kinase Inhibitor, Presented at International Lymphoma Conference
- Positive Results for Unprotected Left Main Coronary Artery PCI With Drug-Eluting Stents
June 24, 2011
- Main Results of the Full Phase I/II study of Amphinex
- Drug Side Effect Linked With Increased Health Risks for Over 65
- RIFM Respiratory Science Program Manager Authors Book on Nanoparticles and Lung Effects
June 27, 2011
- Biota Announces Preliminary Phase III Prophylaxis Trial Results for CS-8959
- Vitae Reports Positive Clinical Data in Chronic Kidney Disease Program at the American Diabetes Association's 71st Scientific Sessions
- American Heart Association Special Reports: Emerging Science Series
- ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
- Recent Study Shows Leukothera Combined with Other Agents Has Enhanced Anti-Leukemia Effects
- Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
June 28, 2011
- Diamyd Medical: TrialNet Presents Results From a Study with Diamyd
- Unigene Presents Positive Advanced Preclinical Data for UGP281 a Potent, Orally Delivered Anorexigenic Peptide in a Late-Breaking Poster Presentation at the American Diabetes Association 71st Scientific Sessions
- Vical Provides Allovectin and Herpes Simplex Vaccine Updates at BIO International Convention
- Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With Mydicar Enzyme Replacement Therapy in the Journal Circulation
- Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
- Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
- Investigational Ultra-Long-Acting Insulin Degludec Reduces Hypoglycemia and Improves Long-Term Control in Patients With Type 1 and Type 2 Diabetes
- New Data Shows Victoza Helped Reduce Blood Sugar When Patients With Type 2 Diabetes Switched From Sitagliptin or Exenatide
- Phase III prophlaxis trial for CS-8958
- Investigational Study Reported ONGLYZA (saxagliptin) Added to Insulin Significantly Improved Blood Sugar Levels in Adults with Type 2 Diabetes Compared to Placebo Added to Insulin
- Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study
- Investigational Compound Dapagliflozin with Metformin Extended-Release (XR) as Initial Combination Therapy Significantly Improved Blood Sugar Control in Previously-Untreated Adult Type 2 Diabetes Patients with High Blood Sugar Levels
- Lantus/Apidra SoloSTAR Help to Improve Patient Satisfaction
- Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
- Sunshine Biopharma's Lead Anti-Cancer Compound, Adva-27a, Performs Exceptionally Well in Human Microsome Stability Assays
- Zealand Pharma presented new preclinical data on ZP2929 in disease models for diabetes and obesity at the American Diabetes Association?s 71st Annual Scientific Sessions
- New data for linagliptin to be presented at the ADA
June 29, 2011
- Newly Published Study Showed Axiron (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
- Amsterdam Molecular Therapeutics' Glybera Significantly Reduces the Risk of Pancreatitis in LPLD Patients
- Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
- Late Breaking Data Presented at the American Diabetes Association 71st Annual Scientific Sessions Evaluate the Safety and Tolerability of TAK-875, Takeda's Investigational Compound for the Treatment of Type 2 Diabetes
- Two Pivotal Phase III Lucentis Studies Showed Patients With Diabetic Macular Edema Experienced Significant Improvements in Vision and Fewer Developed More Advanced Retinopathy
- Additional Data on Provectus's PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
- Mount Sinai Researchers Develop New Gene Therapy for Heart Failure
- QRxPharma Releases Additional Data on Phase 3 Comparative Safety Study for MoxDuo IR
June 30, 2011
- Vectura Group plc email alerting service
- Medicago reports positive Phase II final results for its avian flu pandemic vaccine
- GTx Announces Upcoming Presentations of Effects of Ostarine in Non-Small Cell Lung Cancer Patients at World Conference on Lung Cancer
- Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
- Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
- Nuvo Research Announces Positive Top-Line Results for Pennsaid Viscous Solution Phase 2 Trial
- Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
- Scancell Develops New Vaccine for the Treatment of Lung Cancer
- Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
- The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
- ACORN Research Reports Positive Findings of Phase 2b Metastatic Breast Cancer Trial at ASCO
